Department of Surgery, Institute of Child Health, WCIN IEH London, United Kingdom.
J Pediatr Surg. 2009 Nov;44(11):2192-201. doi: 10.1016/j.jpedsurg.2009.07.028.
Although many serologic markers have been suggested for diagnosis of necrotizing enterocolitis, there is little consensus on which of these is potentially clinically useful. Our aims were (i) to systematically review circulating markers that are potentially useful in the diagnosis of NEC and (ii) to compare the relative performance of each serologic marker of NEC by pooling estimates of marker accuracies and presenting their combined diagnostic accuracies.
We undertook a systematic review of the literature to identify studies that reported serologic markers at the time of diagnosis of necrotizing enterocolitis. Where possible, we constructed 2-by-2 tables of diagnostic accuracy from each article, if 2 or more studies investigated the same test, their results were meta-analyzed by pooling estimates of sensitivity, specificity, likelihood ratio for positive index test (LR+), likelihood ratio for negative index test (LR-), diagnostic odds ratio, and their corresponding 95% confidence intervals.
Twenty-five articles provided information on serology at the time of diagnosis of necrotizing enterocolitis. Of these, it was possible to construct diagnostic accuracy tables from 16 articles and to combine data from studies that used C-reactive protein, intestinal fatty acid binding protein, and platelet-activating factor. Of these C-reactive protein was a sensitive but nonspecific marker for necrotizing enterocolitis, whereas platelet-activating factor and intestinal fatty acid binding protein were both sensitive and specific.
Most serologic markers of necrotizing enterocolitis have been used in too few studies to evaluate their use. Of those tests that have been tested repeatedly, platelet-activating factor and intestinal fatty acid binding protein are potentially useful, although their use must be further tested in larger prospective studies.
尽管有许多血清学标志物被提出用于诊断坏死性小肠结肠炎,但对于哪些标志物具有潜在的临床应用价值,尚未达成共识。我们的目的是:(i)系统地回顾潜在有助于坏死性小肠结肠炎诊断的循环标志物;(ii)通过汇总标志物准确性的估计值并展示其联合诊断准确性,比较每种坏死性小肠结肠炎血清标志物的相对性能。
我们对文献进行了系统回顾,以确定在诊断坏死性小肠结肠炎时报告血清学标志物的研究。如果有 2 项或更多研究调查了相同的检测方法,则尽可能从每篇文章中构建诊断准确性的 2×2 表,如果可能,我们对其结果进行汇总分析,合并敏感度、特异度、阳性似然比(LR+)、阴性似然比(LR-)、诊断比值比(DOR)及其 95%置信区间的估计值。
25 篇文章提供了坏死性小肠结肠炎诊断时的血清学信息。其中,有 16 篇文章可以构建诊断准确性表,并且可以合并使用 C 反应蛋白、肠脂肪酸结合蛋白和血小板激活因子的研究数据。其中 C 反应蛋白是坏死性小肠结肠炎的一种敏感但非特异性标志物,而血小板激活因子和肠脂肪酸结合蛋白均具有敏感性和特异性。
大多数坏死性小肠结肠炎的血清学标志物在评估其应用价值方面使用的研究较少。在已经经过反复测试的测试中,血小板激活因子和肠脂肪酸结合蛋白具有潜在的应用价值,尽管它们的应用必须在更大的前瞻性研究中进一步测试。